ReHeart (Human (Allogeneic) iPS Cell-derived Cardiomyocyte Patches) / Cuorips - LARVOL DELTA

Japan approves commercialization of 2 iPS-derived drugs in world’s first - "The Japanese government on Friday conditionally approved the commercialization of two regenerative medicine products prepared from induced pluripotent stem cells, marking the world's first. The two iPS-derived drugs are ReHeart, developed by Cuorips Inc. to treat patients with severe heart failure stemming from ischemic cardiomyopathy, and Amchepry, produced by Sumitomo Pharma Co. and Racthera Inc. to treat Parkinson's disease. Treatment using the drugs is expected to begin as early as this summer. ReHeart is expected to cost over 10 million yen ($63,500), and Amchepry will also be expensive."

Japan approval • Launch Japan • Pricing • Cardiomyopathy • Parkinson's Disease

Japan panel approves world’s first iPS cell-based therapies (Nikkei) - "The Ministry of Health, Labor and Welfare's committee on regenerative medicine products and biotechnologies approved heart muscle sheets derived from human iPS cells developed by Cuorips, a University of Osaka-born startup. The committee also approved Amchepry, a candidate treatment for Parkinson's disease developed by Japanese drugmaker Sumitomo Pharma....The trials observed symptom improvement in four of six Parkinson's patients, and in all eight heart failure patients."

Japan approval • Parkinson's Disease